Cocrystal pharma stock

Cocrystal pharma stock. Stock Data; SEC Filings; Cocrystal Pharma is a tightknit team of scientific minds and innovators who are passionate about what we do. Includes annual, quarterly and trailing numbers with full history and charts. Monitor the latest movements within the BOTHELL, Wash. 72M. 04%. Quarterly Results. 617. (Nasdaq: COCP) (“Cocrystal” or the “Company”) provides an update on the clinical development of its oral first-in-class pan-norovirus and pan-coronavirus dual protease inhibitor CDI-988 and its oral PB2 inhibitor CC-42344 for the treatment of pandemic and seasonal influenza A. 8100 -0. 27, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. 68%. 64. Cocrystal Pharma has generated ($1. 12, representing an $810. It focuses on the Cocrystal Pharma, Inc. The forecast ranges from a conservative $19. Cocrystal Pharma Inc has a consensus price target of $7 based on the ratings of 1 analysts. Company Overview; 1 Valuation; 2 Future Growth; 3 Past Performance; 4 Financial Health; 5 Dividend; 6 Management; 7 Ownership; Other Information; View Valuation. CONSOLIDATED BALANCE SHEETS (in thousands) September 30, 2022 December 31, 2021 (unaudited) Assets Current assets: Cash $ 42,056 $ 58,705 Restricted cash 75 50 Prepaid expenses and other current assets 2,765 568 Total current assets 44,896 59,323 Property and equipment, net 378 453 Deposits 46 46 Operating lease right-of Stock Data; SEC Filings; Corporate Governance; Contact Us; We are a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of Stock Data; SEC Filings; Corporate Governance; Contact Us; We are a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments. (COCP) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears. 35. 97 per share for proceeds of $4. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. 23, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. The Company reported working capital of $39. Martin served as the Chief Financial Officer of Motus GI (Nasdaq: MOTS), a medical device company. This guy is like the leader of a pod of killer whales Find the latest Cocrystal Pharma, Inc. 100. 7 million as of December 31, 2021. 68% increase from the current price of $2. Outperforming Pharma Stock Ready To Run Higher Pharmaceutical and healthcare giant McKesson (MCK) suffered several pullbacks on the charts in recent weeks, just after touching a record high of Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that pharmacokinetic (PK) data from the single ascending dose portion of a Phase 1 study with its novel, broad-spectrum, orally administered antiviral candidate CC HC Wainwright Adjusts Price Target on Cocrystal Pharma to $42 From $48, Maintains Buy Rating 22-11-07: MT COCRYSTAL PHARMA : HC Wainwright Adjusts Cocrystal Pharma PT to $4 From $4. Cocrystal Pharma Inc stock price live, this page displays NASDAQ COCP stock exchange data. Enterprise Value -2. Weinberg & Company, P. 13, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. Earnings for Cocrystal Pharma are The shares of common stock are being offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. Discover historical prices for COCP stock on Yahoo Finance. CONSOLIDATED BALANCE SHEETS (in thousands) Common stock, $0. 2m. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in BOTHELL, Wash. Additionally, Cocrystal Pharma has announced a significant change in its capital structure with a reduction in the number of authorized capital stock from 155 million to 101 million shares. stock forecast: see what analysts think of Cocrystal Pharma, Inc. 5 Day Performance-13. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis C viruses, influenza viruses, and noroviruses. The Wall Street analyst predicted. equitystock. 74) diluted earnings per share). About Cocrystal Pharma, Inc. COCP Stock Quote - Cocrystal Pharma Stock Price & News - AInvest Aime Copilot Find the latest Cocrystal Pharma, Inc. Jun 30, 2024. 1. , a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. This was a 1 for 12 reverse split, meaning for each 12 shares of COCP owned pre-split, the shareholder now owned 1 share. Common Stock (COCP) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. Sign up for email alerts. CDI-988 targets a highly conserved region in the active site of SARS-CoV-2 main (3CL) protease Cocrystal Pharma, Inc. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class BOTHELL, Wash. , April 24, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. View the latest Cocrystal Pharma Inc. 2. Cocrystal Pharma (NASDAQ: COCP) just reported results for the fourth quarter of 2023. 18%. (COCP) with a description, list of executives, contact details and other key facts. 03, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. Cocrystal employs unique structure-based technologies and Nobel Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts. Cocrystal Pharma Inc. (Nasdaq: COCP) announces highly favorable safety and tolerability results for its orally administered replication inhibitor CC-42344 in its Phase 1 study. Stock Data; SEC Filings; Corporate Governance; Contact Us; We are a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments. stock news by MarketWatch. Latest Financial Results . View real-time stock prices and stock quotes for a full financial overview. Cocrystal employs unique structure-based technologies and Nobel Prize BOTHELL, Wash. COCP Stock Performance. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, Chief Financial Officer and Co-Chief Executive Officer, will present a Company overview at Noble Capital Markets’ 19 th Annual Emerging Growth Equity Conference on Monday, December 4 at 1:30 p. 30M . We are constantly seeking talented individuals with the same passion for discovering and developing novel antiviral therapeutics that target the replication process. 1-Year Change -36. 6 Month Performance +17. Cocrystal Pharma last issued its quarterly earnings results on August 14th, 2024. (COCP) $1. Eastern time. What is the planned Phase 1 study for inhaled CC-42344? The Phase 1 study for inhaled CC-42344 is planned for potential influenza treatment and post-exposure Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial. In the same quarter last year, Cocrystal Pharma's earnings per share (EPS) was-$0. (OTCQB: COCP), (“Cocrystal” or the “Company”), a biotechnology company focused on the discovery and development of novel antiviral EXECUTIVE INTERVIEW - Cocrystal Pharma: Utilizing Structure-Based Technologies to Provide First- & Best-In-Class Antiviral Drugs to Address Critically Unmet Medical Needs Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast. The average Cocrystal Pharma stock price prediction forecasts a potential upside of 291. 11, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three months ended March 31, 2024 Financial ratios and metrics for Cocrystal Pharma (COCP). Future criteria checks 0/6. Ram Selvaraju has given his Buy BOTHELL, Wash. This was above the analyst estimate for EPS of -60 Stock Data; SEC Filings; About Cocrystal Pharma, Inc. (COCP) currently has an average brokerage recommendation (ABR) of 1. 79, and the lowest is $16. 6m. (NASDAQ: COCP) is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of COVID-19 and other Cocrystal Pharma Inc (COCP) stock is projected to chart a bullish course in 2040, with an average price target of $19. , June 20, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. For example, a 1000 share position pre-split, became a 83. , May 04, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. CONSOLIDATED BALANCE SHEETS (in thousands) September 30, 2022 December 31, 2021 (unaudited) Assets Current assets: Cash $ 42,056 $ 58,705 Restricted cash 75 50 Prepaid expenses and other current assets 2,765 568 Total current assets 44,896 59,323 Property and equipment, net 378 453 Deposits 46 46 BOTHELL, WA, Nov. please read this notice carefully and in its entirety. What is the cash balance reported as of March 31, 2024? Cocrystal reported unrestricted cash of $21. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces completion of enrollment of 78 subjects who were infected with influenza A in a randomized, double-blind, placebo-controlled Phase 2a human challenge clinical study evaluating the safety, tolerability, antiviral and clinical measurements EXECUTIVE INTERVIEW - Cocrystal Pharma: Utilizing Structure-Based Technologies to Provide First- & Best-In-Class Antiviral Drugs to Address Critically Unmet Medical Needs Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast. 03 ( Find the latest Cocrystal Pharma, Inc. 18% in one year. The 1 analyst with a 12-month price forecast View Cocrystal Pharma, Inc COCP investment & stock information. Cocrystal Pharma Stock Data; SEC Filings; Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs. Market Cap Chart $ % Since March 12, 2018, Cocrystal Pharma's market cap has decreased COCP Stock Message Board for Investors. 00 on a scale of 1 to 5 (Strong Buy to Single Ascending Dose Portion of Phase 1 Study Completed . According to analysts, Cocrystal Pharma's stock has a predicted upside of 255. 1 million from the sale of common stock through an At-The-Market (ATM) facility in January 2021 and $36. 0 million. 26, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. Log In. 92%) Bid: 0. Key highlights include: 1. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and BOTHELL, Wash. D. The reported ($0. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces the achievement of first-patient-in for the Phase 2a human challenge clinical trial with CC-42344, an investigational new oral antiviral inhibitor for the treatment of pandemic and seasonal influenza A. Food and Drug Administration (FDA) regarding Find annual and quearterly earnings data for Cocrystal Pharma, Inc. Bothell, Washington 19805 North Creek Parkway Bothell, WA 98011. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. Get detailed forecast and price target charts for Cocrystal Pharma, Inc. 1% . PDF HTML Release. View live Cocrystal Pharma, Inc. (NASDAQ: COCP) is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that BOTHELL, WA and ATLANTA, GA -- (Marketwired) -- 11/25/14 -- Cocrystal Pharma, Inc. Favorites Hot ; Monitor The stock is at an all time low and they bring in a guy to package them together with about 4-5 other therapies and get scooped up for pennies on the dollar. 5. Free forex prices, toplists, indices and lots more. Food and Drug Administration (FDA) regarding Cocrystal Pharma (COCP) Company Description: Cocrystal Pharma, Inc. , May 28, 2021 (GLOBE NEWSWIRE) -- With great sadness, Cocrystal Pharma, Inc. Cocrystal Pharma Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Market Cap: US$18. During 2021 the company raised $38. Find the latest Revenue & EPS data for Cocrystal Pharma, Inc. com. “This is an eventful time for Cocrystal with multiple near-term milestones with our highly promising antiviral Cocrystal Pharma, Inc. In a report released today, Ram Selvaraju from H. 06% from the current COCP share price of $1. Google. Overview; Financials; Statistics; Forecast; History; Profile; Chart; Forecast; Analyst Ratings; Cocrystal Pharma Stock Forecast. A. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. 70. that Cocrystal Pharma's share price could reach $7. Find the latest institutional holdings data for Cocrystal Pharma, Inc. From September 2014 to November 2016 he served as the Chief Financial Officer of VBI Vaccines, Inc. , Chairman, CEO and co-founder, suddenly passed away Wednesday, May 26 at the age of 74. , July 29, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in Cocrystal Pharma, Inc. Add to watchlist. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces dosing of the first subjects in the multiple-ascending dose (MAD) portion of the Phase 1 study with CDI-988, its Company profile for Cocrystal Pharma, Inc. Other Robinhood Financial fees may apply, check rbnhd. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing novel small molecule antiviral therapeutics, announces the selection of its novel, oral, broad-spectrum 3CL protease inhibitor CDI-988 as a potential Cocrystal Pharma, Inc. 29, 2021 1 Comment Cocrystal Pharma added to Russell Microcap Index Webull offers Cocrystal Pharma Inc stock information, including NASDAQ: COCP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COCP stock news, and many more online research tools to help you make informed decisions. We have identified promising antiviral therapeutics that target the replication process of influenza viruses, noroviruses and coronaviruses, including SARS-CoV-2 and its variants. Get the latest Cocrystal Pharma, Inc. Watch COCP chart and read a more detailed Cocrystal Pharma, Inc. View the COCP premarket stock price ahead of the market session or assess the after hours quote. (NASDAQ: COCP) is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of COVID-19 and other Stock Data; SEC Filings; Cocrystal Pharma is a tightknit team of scientific minds and innovators who are passionate about what we do. Includes date and ratio. yahoo. future price: according to them, COCP price has a max estimate of 10. View Cocrystal Pharma Inc COCP stock quote prices, financial information, real-time forecasts, and company news from CNN. , July 18, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has received Pre-Investigational New Drug (Pre-IND) feedback from the U. 50, Maintains Buy Rating 21-06-15: MT COCRYSTAL PHARMA : HC Wainwright Adjusts Cocrystal Pharma Price Target to $4. Hassan’s distinguished 40-year career includes serving in senior executive and director positions at global pharmaceutical BOTHELL, Wash. Get a complete stock price history for Cocrystal Pharma, starting from its first trading day. co/fees for details. 00. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class Cocrystal Pharma, Inc. Cocrystal common stock was added to the Russell Microcap COCRYSTAL PHARMA, INC. December 26, 2023 | benzinga. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. 33%. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in Stock Data; SEC Filings; Corporate Governance; Contact Us; We are a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments. Cocrystal’s common stock is expected to begin trading on a split-adjusted basis at commencement of trading on Tuesday, October BOTHELL, Wash. 13). December 6, 2023 . USD USD. Transfer Agent. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. On Tuesday, Noble Capital maintained its Outperform rating on Cocrystal Pharma (NASDAQ:COCP) with a steady price target of $10. Stock Data; SEC Filings; Corporate Governance; About Cocrystal. (COCP) stock price, news, historical charts, analyst ratings and financial information from WSJ. (COCP) stock quote, history, news and other vital information to help you with your stock trading and investing. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class Detailed annual and quarterly income statement for Cocrystal Pharma (COCP). PDF HTML. Phone: 877-COCP123 (877-262-7123) Email: info@cocrystalpharma. USD NASDAQ Capital Market Delayed Price Market Cocrystal Pharma, Inc. Common Stock (COCP) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. The low is $7 issued by HC Wainwright Cocrystal Pharma Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. 1 million as of December 31, 2022 compared with $58. Cocrystal Pharma Single Ascending Dose Portion of Phase 1 Study Completed . October 7, 2024 4:00 PM ET Volume: 23,123. 00 (0. (Nasdaq: COCP) (Cocrystal or the Company) announces the completion of a private placement of 2,030,458 shares of common BOTHELL, Wash. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced it intends to offer shares of its common stock for sale in an underwritten public offering. CONSOLIDATED BALANCE SHEETS (in thousands) June 30, 2021 December 31, 2020 (unaudited) Assets Current assets: Cash $ 67,062 $ 33,010 Restricted cash 50 50 Accounts receivable - 556 Prepaid expenses and other current assets 225 399 Total current Cocrystal Pharma Inc stock price live, this page displays NASDAQ COCP stock exchange data. ) (Nasdaq: VBIV), a pharmaceutical development and manufacturing company. Find the latest Cocrystal Pharma, Inc. Access real-time $Cocrystal Pharma Inc stock insights on eToro. The high is $7 issued by HC Wainwright & Co. 39, representing a +680. 48 by 10. Investor Relations. See upgrades, downgrades, price targets and more from top Wall Street stock analysts. 02. 06, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. 1. (Nasdaq: COCP), (“Cocrystal” or the “Company”) announces that Gary Wilcox, Ph. Market Cap. f/k/a biozone pharmaceuticals, inc. 30 million as of August 15, 2024. 712 x 200 Ask: 2. Common Stock (COCP) at Nasdaq. €1. Sign up today. August 14, 2024. Stock Price, News and Company Updates. Stocks / Pharmaceuticals & Biotech; Cocrystal Pharma DB:8CC Stock Report. Expects topline results in 2025 from Phase 2a influenza A study with oral CC-42344 2. Cocrystal We've gathered analysts' opinions on Cocrystal Pharma, Inc. €16. Cocrystal Pharma (COCP) has 1 split in our Cocrystal Pharma stock split history database. Cocrystal Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial. Cocrystal's stock jumps 25% after CDI-45205 shows encouraging antiviral activity against Delta, Gamma variants SA News Thu, Jul. Discover real-time Cocrystal Pharma, Inc. Log In Or log in with. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class Cocrystal Pharma has a market cap or net worth of $17. 53, missing estimates of -$0. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza virus, SARS-CoV-2 virus, hepatitis C virus, and norovirus. ’s (Nasdaq: COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A (H5N1) PB2 protein recently identified in infected dairy cattle, according to recently completed in vitro studies. 0. Auditor. , April 10, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. View prices, charts, and analyst price target Invest in COCP Now The Cocrystal Pharma Inc (COCP) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $16. Category Nano-Cap. , March 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. 10. Watchlist Compare. Common Stock (COCP) including shareholders, ownership summaries, and holding activities at Nasdaq. Cocrystal Pharma Future Growth. We check hedge fund and billionaire investor sentiment before On Tuesday, Noble Capital maintained its Outperform rating on Cocrystal Pharma (NASDAQ:COCP) with a steady price target of $10. This fee is shown as an annual percentage rate (APR). stock was issued. m. 1 Month Performance +6. 03, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. 2) and Gamma (Brazil/P. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces completion of enrollment of 78 subjects who were infected with influenza A in a randomized, double-blind, placebo-controlled Phase 2a human challenge clinical study evaluating the safety, tolerability, antiviral and clinical measurements By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT No revenues were reported in the 3rd quarter of 2023 Cocrystal Pharma’s (NASDAQ:COCP) as the company’s drug candidates are After reaching an important support level, Cocrystal Pharma, Inc. 00 x 300. 3 Month Performance-17. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. (COCP) history of stock splits. (“cocrystal” or the “company”) common stock (ticker symbol: cocp) as of august 20, 2020, who continue to own such shares through december 16, 2020 (“current cocrystal stockholders”). (Nasdaq: COCP) (Cocrystal or the Company) announces that its Board of Directors has approved a 1-for-12 reverse stock split of the Company’s common stock. The offering of the shares of common stock is being made only by means of a prospectus, Find latest Cocrystal Pharma Inc (COCP) stock discussions and message board on Twitter, StocksTwits, Reddit, SeekingAlpha and other social media About Cocrystal Pharma. Dashboard Portfolios Watchlist Community Discover Screener. BOTHELL, WA, Oct. 69%. 12%) At close: October 25 04:00PM EDT. 5 million, net of transaction costs, which included net proceeds of approximately $2. 00 USD and a min estimate of 7. CDI-988 and CC Cocrystal Pharma Stock Price Performance. Cocrystal Pharma (COCP) reported Q2 2024 earnings per share (EPS) of-$0. 1) variants. Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast November 29, 2023 First-in-Human Study of CC-42344, A Novel Broad-Spectrum Influenza A Polymerase PB2 Inhibitor 7th Annual ISIRV-AVG Conference "Cocrystal Pharma Inc stock price live, this page displays NASDAQ COCP stock exchange data. 74) earnings per share over the last year (($1. Stay ahead COCP | Complete Cocrystal Pharma Inc. The firm's optimism is tied to the anticipated results from the Research Cocrystal Pharma's (Nasdaq:COCP) stock key valuation metrics while comparing it with its industry peers & market side by side. 4 million in net proceeds from a public offering of common stock May 2021. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced the closing of its registered direct offering with two institutional investors for 3,492,063 shares of common stock. LHA Investor Relations Jody Cain T: 310-691-7100 jcain@lhai. 1 Year Performance +7. We are conducting a Phase 2a human challenge study targeting pandemic and seasonal influenza A with an oral PB2 inhibitor, and a Phase 1 study Find annual and quearterly earnings data for Cocrystal Pharma, Inc. CC-42344 is a new class of antiviral drugs designed to block BOTHELL, Wash. Wainwright maintained a Buy rating on Cocrystal Pharma (COCP – Research Report), with a price target of $7. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, presented at the AASLD 2019 Liver Meeting being held November 8-12, 2019 in Boston, MA, new data in a poster demonstrating positive data from its BOTHELL, Wash. Net cash used in operating activities for 2022 was $21. 4 million. (NASDAQ:COCP) is a good investment right now. , May 13, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. Interactive Chart for Cocrystal Pharma, Inc. The Board of Directors and staff of Cocrystal extend their deepest condolences to the COCRYSTAL PHARMA : HC Wainwright Adjusts Cocrystal Pharma PT to $4 From $4. 50 From $5, Maintains Buy Rating 20-11-12: MT. Cocrystal has In this article we will take a look at whether hedge funds think Cocrystal Pharma, Inc. Share your opinion and gain insight from other stock traders and investors. 3333333333333 share BOTHELL, Wash. Get the latest Cocrystal Pharma Inc (COCP) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. COCP updated stock price target summary. This randomized, double About Cocrystal Pharma, Inc. ZIP XLS HTML. stock on Seeking Alpha. Please change to: Cocrystal Pharma, Inc. (COCP) latest earnings report: revenue, EPS, surprise, history, news and analysis. The company develops CC-31244, a HCV non Cocrystal Pharma (Nasdaq: COCP) reported Q2 2024 financial results and provided updates on its antiviral drug development programs. Stock Data; SEC Filings; Corporate Governance; Contact Us ; We are a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments. 001 a par value: 150,000 shares authorized as of March 31, 2024, and December 31, 2023; 10,174 shares issued and outstanding as of March 31, 2024 and December 31, 2023 10 10 Additional paid-in capital 342,445 342,288 Accumulated deficit The value each COCP share was expected to gain vs. Cocrystal previously announced that CDI Stock Data; SEC Filings; Corporate Governance; Email Alerts; Tear Sheet; Contacts; RSS News Feed; Press Releases. , Aug. chart to track its stock's price action. Stock quotes are provided by Factset, Morningstar and S Cocrystal Pharma Inc stock performance at a glance. Cocrystal Pharma is expected to release next earnings COCP News. Q2 2024. Common Stock (COCP) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. Monitor the latest movements within the By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT On January 8, 2024, Cocrystal Pharma (NASDAQ:COCP) released a new investor presentation which can be found here . Company Overview; 1 Valuation; See Cocrystal Pharma, Inc. Monitor the latest movements within the Cocrystal Cocrystal Pharma (COCP) real time stock quotes, news, chart, key statistics and vital financial information with AInvest. Receive COCP Stock News and Ratings via Email. On January 4 - Reverse stock split to be effective on Wednesday, January 24, 2018 on split-adjusted basis under trading symbol “COCPD” - ATLANTA, GA and BOTHELL, WA, Jan. Create real-time notifications to follow any changes in the live stock price. , Dec. COCRYSTAL PHARMA, INC. Sep 26, 2024. 7D. 67. S. From April BOTHELL, WA, Feb. Ranking # 4916. In addition, the Company expects to grant the Cocrystal reported unrestricted cash of $37. 79. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that pharmacokinetic (PK) data from the single ascending dose portion of a Phase 1 study with its novel, broad-spectrum, orally administered antiviral candidate CC Stock Data; SEC Filings; Corporate Governance; Contact Us; We are a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments. 23 to a sky-high $20. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class Cocrystal Pharma, Inc. on August 22, 2024. How much insider buying is happening at Cocrystal Pharma? Cocrystal Pharma Inc () Stock Market info Recommendations: Buy or sell Cocrystal Pharma stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Cocrystal Pharma share forecasts, stock quote and buy / sell signals below. COCP recently experienced a "golden cross" event, which saw its 50 A list of analyst ratings for Cocrystal Pharma (COCP) stock. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing Cocrystal Pharma Submits Pre-Investigational New Drug Briefing Package to the FDA for Clinical Development Guidance of CDI-45205 for COVID-19 Treatment November 1, 2021 Cocrystal Pharma to Present Data from its Oral and Intranasal COVID-19 Therapeutics Programs at the World Antiviral Congress 2021 Cocrystal Pharma (COCP) stock price, charts, trades & the US's most popular discussion forums. (COCP) could be a good stock pick from a technical perspective. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing BOTHELL, Wash. Forgot your password ? Remember. See the latest Cocrystal Pharma Inc stock price (COCP:XNAS), related news, valuation, dividends and more to help you make your investing decisions. 41. analyst ratings, historical stock prices, earnings estimates & actuals. 10-Q Filing. 9m. (COCP) stock news and headlines to help you in your trading and investing decisions. (Nasdaq: COCP) reports financial results for the 12 months ended December 31, 2022, and provides updates on its antiviral pipeline, upcoming milestones and business activities. Message Board Total Posts: 50 BOTHELL, Wash. Mr. View today's Cocrystal Pharma Inc stock price and latest COCP news and analysis. The split for COCP took place on October 11, 2022. the value that each COCP share actually gained. January 23, 2023. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor July 18, 2024 New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected - Reverse stock split to be effective on Wednesday, January 24, 2018 on split-adjusted basis under trading symbol “COCPD” - ATLANTA, GA and BOTHELL, WA, Jan. (Nasdaq: COCP) (Cocrystal or the Company) announces the completion of a private placement of 2,030,458 shares of common stock at a price of $1. 001 par value 150,000 shares authorized as of September 30, 2023, and December 31, 2022; 10,174 and 8,143 shares issued and outstanding as of September 30, 2023 and December 31, 2022 - Reverse stock split to be effective on Wednesday, January 24, 2018 on split-adjusted basis under trading symbol “COCPD” - ATLANTA, GA and BOTHELL, WA, Jan. 00 USD. Common Stock (COCP) including earnings per share, earnings forecasts at Nasdaq. S1Z2d2VhYGmEm5ptsnkAl4kCCqL4_OencPA_ukyW0SJWbDdqAG1fYvLyhw Log in. Its market cap has decreased by -36. Our antivirals target the replication process and are designed to be safe, Get a real-time Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel broad-spectrum antiviral therapeutics that target the replication process of influenza virus, coronaviruses (including SARS-CoV-2 and MERS), norovirus, and Prior to Cocrystal, Mr. 33% based on their 12-month stock forecasts. The firm's optimism is tied to the anticipated results from the Stock Data; SEC Filings; Corporate Governance; Contact Us; We are a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments. is a clinical-stage biotechnology company. Track Cocrystal Pharma Inc (COCP) Stock Price, Quote, latest community messages, chart, news and other stock related information. (OTCQB: COCP), (“Cocrystal” or the “Company”), a biotechnology company focused on the discovery and development of novel antiviral COCP / Cocrystal Pharma, Inc. Apple Sign Stock Data; SEC Filings; Corporate Governance; Contact Us; We are a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments. 04 (-1. a3e2a791a9a5ce6f7eea30652. (COCP), analyze all the data with a huge range of indicators. Common Stock (COCP) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets. 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. 00%) Oct 22, 2024, 4:00 PM EDT - Market closed . . 30, 2019 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. What analysts cover Cocrystal Pharma? Cocrystal Pharma has been rated by research analysts at HC Wainwright in the past 90 days. Investors in the private placement were Cocrystal Director and co-founder Phillip COCRYSTAL PHARMA, INC. Lenders are funds or individuals that own the security that have indicated to the broker that they are willing to lend it out. , March 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. All News; 2024; 2023; 2022; 2021; 2020; 2019; 2018; 2017; 2016; 2015; 2014; Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A. Sign-up to receive the latest news and ratings for Cocrystal Pharma and As of 13-Sep-2024 the stock price of Cocrystal Pharma is $1. According to present data Cocrystal Pharma's COCP shares and potentially its market environment have to: all owners of cocrystal pharma, inc. 7800 -0. 53) earnings per share for the quarter, missing analysts' consensus estimates of ($0. Cocrystal Pharma reported earnings per share of -44 cents. Who are Cocrystal Pharma’s competitors? Compass Therapeutics, Inovio Pharmaceuticals, NexImmune, Marengo Therapeutics, and ImmunityBio are some of the 64 competitors of Cocrystal Research Cocrystal Pharma's (DB:8CC) stock price, latest news & stock analysis. On the Cocrystal Pharma, Inc. | 1,305 followers on LinkedIn. This was above the analyst estimate for EPS of -60 Find the latest analyst research for Cocrystal Pharma, Inc. View daily, weekly or monthly format back to when Cocrystal Pharma, Inc. You can buy and sell Cocrystal Pharma (COCP) and other stocks, ETFs, and options commission-free on Robinhood with real-time quotes, market data, and relevant news. 1 million common shares outstanding as of December 31, 2022. CC-42344 is a broad-spectrum antiviral for the treatment of pandemic and seasonal influenza A with a novel mechanism of action. Miami, Florida 4400 Biscayne Boulevard Miami, FL 33137. short borrow fee rates are shown in the following table. Cocrystal Pharma Engages Investors at Upcoming Conferences TipRanks 20 days ago COCP Stock Earnings: Cocrystal Pharma Misses EPS for Q2 2024 InvestorPlace 26 days ago Find the latest news headlines from Cocrystal Pharma, Inc. Monitor the latest movements within the During 2021 the company raised $38. com www. 27%. Stock analysis for Cocrystal Pharma Inc (COCP:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. (Nasdaq: COCP) (Cocrystal or the Company) announces the appointment of Fred Hassan to its Board of Directors, increasing its Board membership to six. 8 million as of March 31, 2024. 72Year range: 1-3Market cap: COCP stock results show that Cocrystal Pharma missed analyst estimates for earnings per share the second quarter of 2024. , Nov. December 6, 2023 | finance. Cocrystal Pharma Highlights its Novel Inhaled and Cocrystal Pharma Inc (COCP) stock is projected to chart a bullish course in 2040, with an average price target of $19. Equity Stock Transfer 237 W 37th St #601 New York, NY 10018 info@equitystock. (Nasdaq: COCP) (Cocrystal or the Company) announces receipt of authorization from the United Kingdom Medicines and Stock Data; SEC Filings; Corporate Governance; Email Alerts; Tear Sheet; Contacts; RSS News Feed; Contacts. Share your ideas and get valuable insights from the community of like minded traders and investors See the latest Cocrystal Pharma Inc stock price (COCP:XNAS), related news, valuation, dividends and more to help you make your investing decisions. (COCP) stock price quote with breaking news, financials, statistics, charts and more. (COCP) NASDAQ: COCP · Real-Time Price · USD. 08, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) today reported favorable safety and tolerability results from the Cocrystal Pharma (COCP) Quote Overview » More Research » Cocrystal Pharma (COCP) Price Target Stock Forecast Better trading starts here. (formerly SciVac Therapeutics, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Currency in USD. Last Price. “This is an eventful time for Cocrystal with multiple near-term milestones with our highly promising antiviral Find the latest Cocrystal Pharma Inc (COCP) discussion and analysis from iHub's community of investors. NasdaqCM - NasdaqCM Delayed Price. Get the latest Cocrystal Pharma, Inc COCP detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. 1600 (-8. Raymond Schinazi. OD1HMFIVJwe0394lwD9HruF6fduxqd-XQZhOgjnAiHA. This table shows the interest rate that must be paid by a short seller of US:COCP to the lender of that security. 62-1. Find market predictions, COCP financials and market news. At the Supplyside West tradeshow this week representatives from Cocrystal Health Industry are announcing the launch of the Cocrystal Lutein and Curcumin powder actives. CONSOLIDATED BALANCE SHEETS (in thousands) Common stock $0. (COCP) stock discussion in Yahoo Finance's forum. Be the first to receive breaking news. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class Cocrystal Pharma Inc stock price live, this page displays NASDAQ COCP stock exchange data. , Oct. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). and suggest that you do with its stocks. HTML Financials. NasdaqCM:COCP Stock Report. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the three and nine months ended September 30, 2023 The stock symbol for Cocrystal Pharma is COCP. 50, Maintains Buy Rating 21-06-15: MT COCRYSTAL PHARMA, INC. Read Press Release. 7: Day range: 1. 51) by $0. BOTHELL, Wash. Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor Which Cocrystal Pharma insiders have been buying company stock? The following insider purchased COCP shares in the last 24 months: Phillip Md Et Al Frost ($2,000,001. Includes open, high, low, close and volume. Find the latest Cocrystal Pharma, Inc. Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A. (Nasdaq: COCP) announces the selection of its novel, broad-spectrum antiviral drug candidate CDI-988 for clinical development as an oral treatment for SARS-CoV-2, the virus that causes COVID-19. (OTCQB: COCP), a biotechnology company developing novel antiviral therapeutics for human diseases, today announced the closing of its merger with RFS Pharma, LLC, a privately owned biotech company founded by renowned drug developer, Dr. 04, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. , Jan. 58% surge from its current level. Stock Price $1. (OTCQB: COCP), (“Cocrystal” or the “Company”), a biotechnology company focused on the discovery and development of novel antiviral Cocrystal Pharma Stock (NASDAQ:COCP) Dividends: History, Yield and Dates. All Analysts Top Analysts Stock Price Forecast. 5 weeks ago - Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences - GlobeNewsWire 6 weeks ago - CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event - Accesswire 5 months ago - Cocrystal Pharma Reports First Quarter 2024 Financial Results BOTHELL, Wash. 31, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. , July 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. Find everything from its Valuation, Future Growth, Past Performance and more. (COCP) Price Targets See Cocrystal Pharma, Inc. 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. , May 01, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. CDI-988 and CC What is the recommendation for Cocrystal Pharma, Inc. , Sept. The company is headquartered in Stock Data; SEC Filings; Corporate Governance; Contact Us ; We are a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments. See many years of revenue, expenses and profits or losses. 00 by Aug 22, 2025. Year-To-Date Performance +5. analysts consensus, targets, ratings and recommendations | Nasdaq: COCP | Nasdaq. (Nasdaq: COCP) (“Cocrystal” or the “Company”) provides an update on the clinical development of its oral first-in Cocrystal Pharma, Inc. 001 par value; 150,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 10,174 BOTHELL, Wash. 11, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. 43%. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class Cocrystal Pharma (NASDAQ: COCP) just reported results for the fourth quarter of 2023. Previous close: 1. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces the presentation of favorable data demonstrating activity of its potent broad-spectrum PB2 inhibitor CC-42344 against pandemic and seasonal influenza A strains at the World Vaccine Congress West Coast. In vitro testing shows CC-42344 inhibits avian influenza A (H5N1) PB2 protein Cocrystal Pharma, Inc. The highest analyst price target is $16. 333-237738) originally filed with the Securities and Exchange Commission (the "SEC") on April 17, 2020, and declared effective by the SEC on May 13, 2020. Market Cap 17. 0 million and 8. C. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Check Cocrystal Pharma Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. stock? + Cocrystal Pharma, Inc. (COCP) Add to watchlist. What is the current market cap of Cocrystal Pharma? The current market capitalization of Cocrystal Pharma is $17M. 42%. Click here to see the forecast for COCP stock Prior to Cocrystal, Mr. 79 -0. pkod tzodii xgyyonfr oos wtbzycg ohrtt beszad cinmc cixgg zcuxjcj